ERBB2 and breast cancer: HER2-positive BCs account for 20–30% of all BC types (10, 11), and the amplification and overexpression of the HER2 gene is strongly associated with high degree of malignancy, insensitivity to conventional chemotherapy, and poor clinical prognosis in BC (12, 13).